Wave Life Sciences Initiates Phase 2A Combination Trial Of WVE-007 (GalNAc-siRNA) With Tirzepatide For Obesity
Wave Life Sciences Ltd. NASDAQ:WVE
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 aloneMaintenance clinical trial evaluating WVE-007’s ability to curtail weight r…
WVE - Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE - Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
WVE Initiates Phase 2a Trial
Wave Life Sciences initiates Phase 2a portion of INLIGHT trial of WVE-007 for obesity and cardiometabolic diseases